Stock Events

Stock Events

Nautilus Biotechnology 

$0.9049
54
-$0.01-1.59% Friday 20:00
+$0.01+1.39%Friday 23:59After hours

Statistics

Day High
0.9077
Day Low
0.901
52W High
4.31
52W Low
0.652
Volume
18,708
Avg. Volume
-
Mkt Cap
115.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.16
-0.14
-0.13
-0.11
Expected EPS
-0.14
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-59MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NAUT. It's not an investment recommendation.
Hims & Hers Health
13
HIMS
Amazon
12
AMZN
Alphabet
11
GOOGL
Meta Platforms
10
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides genomics solutions, including sequencing technologies that compete in the broader biotech market for genetic analysis.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers long-read sequencing technologies, directly competing in the genomic analysis space.
Qiagen NV
QGEN
Mkt Cap8.9B
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the life sciences sector.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific offers a wide range of biotechnology products, including analytical instruments and reagents, competing in the research and diagnostics markets.
Bio-Rad Laboratories
BIO
Mkt Cap10.37B
Bio-Rad Laboratories provides a variety of instruments and reagents for the life science research and clinical diagnostics markets, making it a competitor in biotech supplies.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing in the precision medicine and genomics field.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the genomic medicine sector, particularly in gene editing.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing in the gene editing and therapy market.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine works on gene editing technologies, competing in the development of genomic medicines for various diseases.

About

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Show more...
CEO
Sujal Patel
Employees
130
Country
United States
ISIN
US63909J1088

Listings

XNAS
US
NAUT
BOATS
BOATS
NAUT.BOATS

0 Comments

Share your thoughts

FAQ

What is Nautilus Biotechnology stock price today?▼
The current price of NAUT is $0.90 USD — it has decreased by -1.59% in the past 24 hours. Watch Nautilus Biotechnology stock price performance more closely on the chart.
What is Nautilus Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Nautilus Biotechnology stocks are traded under the ticker NAUT.
Is Nautilus Biotechnology stock price growing?▼
NAUT stock has risen by +2.17% compared to the previous week, the month change is a -2.7% fall, over the last year Nautilus Biotechnology has showed a +36.9% increase.
What is Nautilus Biotechnology market cap?▼
Today Nautilus Biotechnology has the market capitalization of 115.15M
When is the next Nautilus Biotechnology earnings date?▼
Nautilus Biotechnology is going to release the next earnings report on November 03, 2026.
What were Nautilus Biotechnology earnings last quarter?▼
NAUT earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.14 USD resulting in a +18.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nautilus Biotechnology revenue for the last year?▼
Nautilus Biotechnology revenue for the last year amounts to 0 USD.
What is Nautilus Biotechnology net income for the last year?▼
NAUT net income for the last year is -59M USD.
How many employees does Nautilus Biotechnology have?▼
As of September 05, 2026, the company has 130 employees.
In which sector is Nautilus Biotechnology located?▼
Nautilus Biotechnology operates in the Health & Wellness sector.
When did Nautilus Biotechnology complete a stock split?▼
Nautilus Biotechnology has not had any recent stock splits.
Where is Nautilus Biotechnology headquartered?▼
Nautilus Biotechnology is headquartered in SEATTLE, United States.